Association of LEF1-AS1 with cardiovascular and neurological complications of COVID-19

Journal of molecular and cellular cardiology plus Pub Date : 2024-12-22 DOI:10.1016/j.jmccpl.2024.100280

Mélanie Vausort , Andrew I. Lumley , Hassina Boubakeur , Lu Zhang , Feng Q. Hefeng , Markus Ollert , Paul Wilmes , Guy Fagherazzi , Yvan Devaux

{"title":"Association of LEF1-AS1 with cardiovascular and neurological complications of COVID-19","authors":"Mélanie Vausort , Andrew I. Lumley , Hassina Boubakeur , Lu Zhang , Feng Q. Hefeng , Markus Ollert , Paul Wilmes , Guy Fagherazzi , Yvan Devaux","doi":"10.1016/j.jmccpl.2024.100280","DOIUrl":null,"url":null,"abstract":"<div><div>A significant proportion of COVID-19 patients develop long-term complications, particularly cardiovascular and neurological issues. Even though risk factors for developing complications after COVID-19 have been identified, a biomarker to predict these complications could enable personalized healthcare and potentially reduce the disease burden. Easily measurable in the blood, the long noncoding RNA LEF1-AS1 has recently been associated with in-hospital mortality following SARS-CoV − 2 infection and holds potential as a biomarker for disease severity in COVID-19 patients. Consequently, we examined LEF1-AS1's ability to predict cardiovascular and neurological complications after COVID-19. LEF1-AS1 has been measured in the blood by quantitative PCR in 104 primo-infected participants from the Predi-COVID cohort within 3 days post clinical PCR-confirmed COVID-19 diagnosis. Among them, 35 participants (34 %) reported at least one persistent cardiovascular symptom and at least one persistent neurological or ocular symptom in a self-administered questionnaire 12 months after COVID-19 diagnosis. Blood levels of LEF1-AS1 at baseline in these patients were lower (<em>p</em> = 0.019) compared to those who did not report symptoms. Lower LEF1-AS1 levels were associated with symptoms with an odds ratio of 0.48 (95 % confidence interval 0.28–0.83) in a logistic regression model adjusted for age, sex, comorbidity, and moderate disease severity at baseline. LEF1-AS1 expression was positively correlated with the frequency of naïve T cells and negatively correlated with the frequency of effector memory T cells among total CD8+ T cells, revealing a potential association between LEF1-AS1 and CD8+ T-cell differentiation following SARS-CoV-2 infection. In conclusion, blood levels of LEF1-AS1 can potentially help in predicting 12-month cardiovascular and neurological complications in COVID-19 patients, though this finding requires validation in larger cohorts.</div></div>","PeriodicalId":73835,"journal":{"name":"Journal of molecular and cellular cardiology plus","volume":"11 ","pages":"Article 100280"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of molecular and cellular cardiology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772976124001338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

A significant proportion of COVID-19 patients develop long-term complications, particularly cardiovascular and neurological issues. Even though risk factors for developing complications after COVID-19 have been identified, a biomarker to predict these complications could enable personalized healthcare and potentially reduce the disease burden. Easily measurable in the blood, the long noncoding RNA LEF1-AS1 has recently been associated with in-hospital mortality following SARS-CoV − 2 infection and holds potential as a biomarker for disease severity in COVID-19 patients. Consequently, we examined LEF1-AS1's ability to predict cardiovascular and neurological complications after COVID-19. LEF1-AS1 has been measured in the blood by quantitative PCR in 104 primo-infected participants from the Predi-COVID cohort within 3 days post clinical PCR-confirmed COVID-19 diagnosis. Among them, 35 participants (34 %) reported at least one persistent cardiovascular symptom and at least one persistent neurological or ocular symptom in a self-administered questionnaire 12 months after COVID-19 diagnosis. Blood levels of LEF1-AS1 at baseline in these patients were lower (p = 0.019) compared to those who did not report symptoms. Lower LEF1-AS1 levels were associated with symptoms with an odds ratio of 0.48 (95 % confidence interval 0.28–0.83) in a logistic regression model adjusted for age, sex, comorbidity, and moderate disease severity at baseline. LEF1-AS1 expression was positively correlated with the frequency of naïve T cells and negatively correlated with the frequency of effector memory T cells among total CD8+ T cells, revealing a potential association between LEF1-AS1 and CD8+ T-cell differentiation following SARS-CoV-2 infection. In conclusion, blood levels of LEF1-AS1 can potentially help in predicting 12-month cardiovascular and neurological complications in COVID-19 patients, though this finding requires validation in larger cohorts.

Abstract Image